NCT03525405View on ClinicalTrials.gov

A Study to Evaluate the Mass Balance of 14C-Napabucasin in Healthy Adult Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

May 18, 2018

Primary Completion Date

June 2, 2018

Study Completion Date

June 2, 2018

Conditions
ADMEHealthy
Interventions
DRUG

napabucasin

Single 240 mg dose containing 100 μCi of 14C-napabucasin will be administered with 240 mL of water following an overnight fast.

Trial Locations (1)

53704

Covance Clinical Research Unit, Madison

All Listed Sponsors
lead

Sumitomo Pharma America, Inc.

INDUSTRY

NCT03525405 - A Study to Evaluate the Mass Balance of 14C-Napabucasin in Healthy Adult Male Subjects | Biotech Hunter | Biotech Hunter